Interview, Fireside Chat, Conference Presentation
Memorial Sloan Kettering Cancer Center’s CEO on the Future of Cancer Treatment
- Training large language models on unique Memorial data including x-rays, pathology slides, and laboratory values is expected to improve patient outcome predictions beyond current methods, with Dr. Selwyn Vickers characterizing this capability as a potential "game changer in healthcare."
- Healthcare data generation is predicted to match the total volume produced over the previous five years within the next two years, with AI and data management anticipated to have their greatest impact in oncology due to the high volume of available cancer data.
- In a 20-year forecast, medical science is expected to possess significantly greater knowledge regarding individual cancer risk and treatment methods, with computational oncology projected to enable polygenic risk scores to predict breast and prostate cancer risks more accurately than current standard monitors like PSA without requiring single gene identification.
- mRNA vaccines developed with BioNTech are anticipated to create future opportunities for treating colorectal, esophageal, triple-negative breast, and metastatic prostate cancers.
- Immunotherapy for patients with mismatch repair deficiency, found in 5 to 7% of colon cancer cases, is expected to provide a complete cure without surgery, radiation, or chemotherapy, applying a 100% cure rate observed in an initial under-30 cohort to an expanded group of 117 patients.
- Plans include implementing this immunotherapy protocol as global standard care, specifically targeting Nigeria where 30% of colon cancers carry the relevant genetic defect, aiming to offer curative chances to populations with higher risk but less access to standard infrastructure.
- A 30% increase in cancer incidence among the under-50 cohort is projected between 2019 and 2030, specifically citing a 15 to 20% rise in colorectal cancer incidence among individuals under 40, while the upward trend in pancreatic cancer cases is expected to continue annually.
- GLP-1 inhibitors are identified as having significant potential to address obesity-related cancer drivers, though no strong evidence currently supports microplastics as a single environmental cause for the rise in young-onset cancer; conversely, exercise such as walking two miles daily is cited as reducing cancer risk by 30% in men with cardiac disease.
- Although early detection MRI technology costs are approximately $1,000, prices are forecasted to drop to $500, yet risks include unnecessary biopsies or surgeries for benign findings if patients lack physician guidance during a "diagnostic odyssey."
- Less than 10% of Americans at risk for lung cancer are predicted to currently utilize reimbursed low-dose CT scans, while liquid biopsies are anticipated to improve in their ability to accurately confirm the absence of certain cancers despite limitations in definitive diagnosis.
- Vaccine therapy aims to alter the trajectory for pancreatic cancer, where 90% of patients surviving the Whipple procedure typically die within two years due to minimal residual disease, with goals of maintaining 90% of vaccinated patients alive at five years.
- It is predicted that for patients 10 years post-cancer, the immune system becomes "turbocharged" to prevent recurrence, making a return of the cancer highly unlikely.
- Regarding the job market, the outlook suggests that individuals excelling in their specific fields will find opportunities regardless of overall market saturation.